The association between cognitive functioning and health-related quality of life in low-grade glioma patients by Boele, Florien W et al.
The association between cognitive functioning and health-related
quality of life in low-grade glioma patients
Florien W. Boele†, Maaike Zant†, Emma C.E. Heine, Neil K. Aaronson, Martin J.B. Taphoorn, Jaap C. Reijneveld,
Tjeerd J. Postma, Jan J. Heimans, and Martin Klein
Department of Medical Psychology , VU University Medical Center, Amsterdam, the Netherlands (F.W.B., M.Z., E.C.E.H., M.K.); Department
of Neurology, VU University Medical Center, Amsterdam, the Netherlands (J.J.H., T.J.P., J.C.R.); Department of Neurology, Medical Center
Haaglanden, The Hague, the Netherlands (M.J.B.T.); Division of Psychosocial Research and Epidemiology, The Netherlands Cancer
Institute, Amsterdam, the Netherlands (N.K.A.)
Corresponding author: Florien W. Boele, MSc, Department of Medical Psychology, D-345, VU University Medical Center, Van der Boechorststraat 7, 1081
BT Amsterdam, the Netherlands (f.boele@vumc.nl).
†These authors contributed equally to this work.
Background. Glioma patients are not only confronted with the diagnosis and treatment of a brain tumor, but also with changes in
cognitive and neurological functioning that can profoundly affect their daily lives. At present, little is known about the relationship
between cognitive functioning and health-related quality of life (HRQOL) during the disease trajectory. We studied this association
in low-grade glioma (LGG) patients with stable disease at an average of 6 years after diagnosis.
Methods. Patients and healthy controls underwent neuropsychological testing and completed self-report measures of generic (MOS
SF36) and disease-specific (EORTC BN20) HRQOL. Associations were determined with Pearson correlations, and corrections for multiple
testing were made.
Results. We analyzed data gathered from 190 LGG patients. Performance in all cognitive domains was positively associated with phys-
ical health (SF36 Physical Component Summary). Executive functioning, processing speed, working memory, and information process-
ing were positively associated with mental health (SF36 Mental Component Summary). We found negative associations between a
wide range of cognitive domains and disease-specific HRQOL scales.
Conclusions. In stable LGG patients, poorer cognitive functioning is related to lower generic and disease-specific HRQOL. This confirms
that cognitive assessment of LGG patients should not be done in isolation from assessment of its impact on HRQOL, both in clinical and
in research settings.
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Gliomas are the most common primary malignant brain tumors,
with an incidence of 5 to 7 per 100 000 persons.1 A minority of
gliomas can be histologically defined as low-grade (WHO grade
I or II).
Patients diagnosed with low-grade glioma (LGG) have a more
favorable prognosis than those diagnosed with more rapidly pro-
gressing tumors;2,3 however, the diagnosis and treatment can
have a great impact on their lives. In addition, LGG patients find
themselves confronted with focal neurological limitations, includ-
ing loss of motor functioning, visual-perceptual deficits, sensory
loss,4 and epilepsy, which affects 85% of LGG patients.5 More-
over, cognitive impairment is often associated with LGGs6,7 with
patients experiencing deterioration in a broad array of cognitive
domains (eg, information processing, attention, psychomotor
speed, and memory) when compared with control groups.6 – 8
While the prognostic value of cognitive functioning has been
demonstrated for survival in glioma patients,9 – 12 relatively little
is known about its relationship to patients’ daily functioning.
A small study among long-term survivors of malignant supraten-
torial brain tumors suggests that even subtle cognitive deficits
might hamper a patient’s autonomy and professional life.13
In addition, indices of neurological functioning, such as epilepsy
burden, have been shown to be related to both lower objective
cognitive functioning and self-reported health-related quality of
life (HRQOL) in LGG patients.14 With the high incidence of cogni-
tive and neurological deficits and poorer self-reported HRQOL in
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LGG patients,15,16 a relationship between cognitive functioning
and generic and disease-specific HRQOL would be expected. How-
ever, to our knowledge, these associations have not yet been ex-
amined in depth. Previous studies that examined both cognitive
functioning and HRQOL did not formulate these associations as
their primary study objective and consequently yielded only
brief reports with little detail.14,15 However, it is of particular im-
portance to know the clinical and functional significance of cog-
nitive impairment for clinicians and patients. The clinical
relevance of cognitive deficits cannot be fully appreciated without
assessing their impact on the patient’s quality of life (QOL). Apart
from these possible clinical implications, a separate investigation
into the nature and strength of the correlation between these fac-
tors is also merited because of the increased value being attrib-
uted to both cognitive functioning and HRQOL as secondary
endpoints in glioma clinical trials.17,18
Materials and Methods
Participants
Data for this study were collected as part of a nationwide study of
cognitive functioning and HRQOL of glioma patients. The method-
ology of these studies has been described in detail elsewhere.7 In
short, LGG patients were diagnosed an average of 6 years prior to
data collection and were included in the study if they had (i) been
diagnosed with a histologically confirmed low-grade astrocyto-
ma, oligodendroglioma, or oligoastrocytoma at least 1 year
prior to study entry; (ii) no clinical signs of tumor recurrence for
at least 1 year after diagnosis and primary treatment; (iii) no ra-
diological signs of recurrence within 3 months before the first as-
sessments were performed, (iv) no current treatment with
corticosteroids; and (v) basic proficiency in the Dutch language.
In addition, we included data from 2 samples of healthy con-
trols. Specifically, for comparison on cognitive performance, we
employed a reference sample from the Maastricht Aging
Study,19 a large cross-sectional study on the biological and psy-
chological determinants of cognitive aging. Reference data for
the HRQOL assessments were selected from a national study
aimed at constructing a Dutch version of the Short-Form Health
Survey.20 All healthy controls were matched to the participant
group for age, sex, and educational level.
Procedure
Participants were asked to provide information about their socio-
demographic background via a structured interview. Clinical data
were obtained from the medical records. Participants completed
the self-report measures of generic (SF36) and disease-specific
(BN20) HRQOL and the neuropsychological tests either at home
or at their treating hospital. Neuropsychological assessments
were performed by a trained test assistant, who was supervised
by a board certified neuropsychologist (M.K.). The institutional re-
view boards of the participating centers approved the research
protocol, and all participants provided written, informed consent.
Outcome Measures
Cognitive performance was assessed using an extensive battery of
standardized neuropsychological tests, described in detail in
Table 1.21 – 26 Tests included measures of executive functioning
(categoric word fluency task,21 concept shifting task25), processing
speed (concept shifting task,25 letter digit substitution test24), ver-
bal memory (visual verbal learning test23), working memory
(memory scanning test26), information processing (letter digit sub-
stitution test24), and attention (Stroop color word test22).
Self-reported HRQOL was measured with the Dutch version of
the 36-Item Short-Form Health Survey (SF36).20 The SF36 yields 2
component summary scores: one for physical health (PCS) and
one for mental health (MCS). The PCS and MCS employ norm-
based scoring, with a mean of 50 and a standard deviation of
10. The Dutch version of the SF-36 is a valid and reliable instru-
ment, yielding a mean coefficient alpha of 0.84 across scales.20
Disease-specific HRQOL was measured with the Dutch version
of the EORTC brain cancer module (EORTC QLQ-BN20).27 This
module contains 4 multi-item scales (future uncertainty, visual
disorders, motor dysfunctions, communication deficits) and 7
Table 1. Neuropsychological tests and corresponding cognitive domains
Cognitive domain Content
Executive
functioning
Categoric Word Fluency Task21
Measures executive functioning and semantic
memory. Outcome variable: number of animals
in 60 seconds
Concept Shifting Test25
Measures attention, visual search, mental
processing speed, and ability to mentally control
simultaneous stimulus patterns. Outcome
variables: CST A, CST B, CST C.
Processing speed Concept Shifting Test25
Outcome variable: CST 0
Letter Digit Substitution Test24
Measures psychomotor speed that is relatively
unaffected by a decline in intellectual ability.
Outcome variable: LDST Delta (ie, number of
substitutions read minus number of substitutions
written).
Verbal memory Visual Verbal Learning Test23
Examines verbal learning capacity and
consolidation of verbal information into
long-term memory. Outcome variables: Trial 1,
delayed recall, delayed recognition, and
difference between maximum score and trials 1,
total score trial 1-5)
Working memory Memory Scanning Test26
Measures the speed and efficiency of memory
retrieval processes. Outcome variables/items to
be stored in working memory: symbol ‘%’, 1, 2, 3,
and 4 letters, successively.
Information
processing
Letter Digit Substitution Test24
Outcome variables: number of substitutions read
and written.
Attention Stroop Color Word Test22
Examines information processing speed, selective
attention, and mental control.
Outcome variables: Stroop card I, Stroop card II,
Stroop card III.
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single items assessing headaches, seizures, drowsiness, hair loss,
itching, weakness in the legs, and difficulties with bladder control.
Scores range from 0 to 100, with higher scores indicating more
symptoms. The BN20 scales have high internal consistency reli-
ability (alpha. 0.70) and show overall adequate psychometric
properties.27 Although the BN20 is often administered alongside
the EORTC QLQ-C30, unfortunately, we have no data regarding
this cancer-specific HRQOL questionnaire.
Statistical Analysis
All statistical analyses were performed using the Statistical Pack-
age for Social Science version 20.0 (SPSS). Standard scoring rules
were used to convert the data from the questionnaires. The neuro-
psychological test scores were transformed into Z scores using the
mean and standard deviations (SDs) of the healthy controls, and 6
cognitive domains were created for the purpose of data reduction
(Table 1). To calculate each domain, z scores of the outcome var-
iables were summed up and divided by the number of variables per
domain. Higher scores indicate better performance in all domains.
Sociodemographic characteristics, HRQOL, and cognitive func-
tioning of the LGG group and the control groups were compared
using univariate analysis of variance (ANOVA) and the chi-square
statistic. A 2-sided P value, .05 was considered significant. To ex-
amine the associations between cognitive functioning and both
generic (SF36 component summaries MCS and PCS) and disease-
specific HRQOL (BN20 scales future uncertainty, visual disorders,
motor dysfunctions, communication deficits, headaches, seizures,
and drowsiness), Pearson correlations were calculated. To adjust
for multiple testing, corrections were applied for the 6 cognitive
outcome measures. A 2-sided P value, .0083 was required as ev-
idence of statistical significance for all Pearson correlations shown.
Results
Demographic Characteristics
In total, 239 eligible LGG patients were invited for participation, of
whom 82% (n¼ 195) were included in the study. The main rea-
sons reported for declining participation were the perceived
Table 2. Demographic characteristics of low-grade glioma patients and healthy controls
LGG Patients (n¼ 195) Healthy Controls (cognition; n¼ 195) Healthy Controls (HRQOL; n¼ 195) P value
Age in years M (SD) 40.80 (11.62) 40.55 (12.01) 39.68 (2.32) .494
Sex
Male 120 (61.5%) 121 (62.1%) 122 (62.6%) .978
Female 75 (38.5%) 74 (37.9%) 73 (37.7%)
Educational level n (%) .285
Low 58 (29.7%) 55 (28.2%) 61 (31.3%)
Middle 74 (37.9%) 76 (39.0%) 80 (41.0%)
High 60 (30.8%) 64 (32.8%) 54 (27.7%)
Other 3 (1.5%) N/A N/A
Marital status n (%) ,.001
Single 56 (28.7%) 27 (13.8%) 29 (14.9%)
Married/living with partner 124 (63.6%) 161 (82.6%) 164 (84.1%)
Divorced 6 (3.1%) 5 (2.6%) 0 (0%)
Widow(er) 6 (3.1%) 2 (1.0%) 0 (0%)
Tumor grade n (%) N/A N/A N/A
Grade I 21 (10.8%)
Grade II 174 (89.2%)
Tumor location n (%) N/A N/A N/A
Frontal 47 (24.1%)
Temporal 33 (16.9%)
Parietal 19 (9.7%)
Occipital 5 (2.6%)
Mixed 89 (45.6%)
Other 2 (1.0%)
Tumor lateralization n (%)* N/A N/A N/A
Left 85 (43.6%)
Right 87 (44.6%)
Bilateral 9 (4.6%)
Time since diagnosis Months N/A N/A N/A
M (SD) 66.99 (43.96)
(range) 0–258
*Information on tumor lateralization was missing in 14 cases.
Abbreviations: LGG, low-grade glioma; M (SD), mean, standard deviation; N/A, not applicable.
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burden of participating and not wanting to be confronted with
their disease history. In 5 cases, data were incomplete, leaving
190 LGG participants for the present analyses. No statistically sig-
nificant differences between the participants and the healthy
controls were found for age, sex, and educational level, indicating
an adequate matching procedure (Table 2). Most LGG participants
were men (61.5%), and most received middle to high levels of
education. The majority of participants were married or lived
together with their partner (63.6%).
Cognitive Functioning and Health-related Quality of Life
LGG participants had lower scores than healthy controls on all
cognitive domains that were assessed (P, .001 for all domains
except the verbal memory domain (P¼ .009); see Fig. 1. Further-
more, we found lower self-reported mental health in LGG patients
(MCS, M¼ 46.09; SD¼ 9.81) than in healthy controls (M¼ 49.91;
SD¼ 9.92; P, .001). No statistically significant differences were
observed in physical health between LGG patients and healthy con-
trols (PCS, M¼ 49.92; SD¼ 9.11 vs M¼ 51.28; SD¼ 7.86; P¼ .119).
Associations Between Cognitive Functioning and Generic
(SF36) and Disease-specific (BN20) Health-related
Quality of Life
Cognitive Functioning and Generic (SF36) Health-related
Quality of Life
Better performance on all of the cognitive domains that we as-
sessed was associated with significantly better self-reported
physical health (Table 3 PCS; all P, .001). Furthermore, better
performance on executive functioning, processing speed, working
memory capacity, and information processing speed was associ-
ated with better mental health (MCS, r¼ 0.270, r¼ 0.318, r¼
0.250, and r¼ 0.267, respectively; all P≤ .001).
Cognitive Functioning and Disease-specific (BN20)
Health-related Quality of Life
Regarding cognitive functioning and disease-specific HRQOL as
assessed by the BN20, many negative correlations of weak to
moderate strength were found (Table 4). All cognitive domains
were negatively correlated with the BN20 scales for uncertainty
concerning the future, motor dysfunctions, and seizures. This in-
dicates that worse cognitive performance is associated with more
symptoms, as assessed by these scales.
Participants who had lower executive functioning, processing
speed, working memory capacity, information processing speed,
and attentional functioning were characterized by more symp-
toms of visual disorders. Furthermore, worse performance on in-
formation processing tasks and attention tasks was related to
more difficulty with communication. Patients who had a lower in-
formation processing speed also reported more drowsiness.
Discussion
It is often assumed, but has never actually been demonstrated,
that cognitive functioning in brain tumor patients is related to
their HRQOL. We tested this assumption in a large cohort of low-
grade glioma participants with stable disease, at an average of 6
years after diagnosis. We found that many aspects of physical
functioning, as measured with the SF36 and BN20, were associ-
ated with many, if not all, cognitive domains. Furthermore, poorer
mental health (MCS) and more uncertainty concerning the future
were related to lower cognitive functioning. These results suggest
that LGG patients in a stable phase of their disease may be both-
ered by cognitive deficits that negatively affect their everyday life
functioning. The present study outcomes concur with those of
Giovagnoli and Boiardi,13 who reported that asymptomatic, long-
term glioma survivors may experience limitations in their auton-
omy, even with subtle cognitive deficits. In addition, severe cog-
nitive dysfunction was related to worse levels of HRQOL in
patients with a benign (WHO grade I) meningioma.28
Fig. 1. Cognitive performance of low-grade glioma patients relative to their healthy controls at the 0-line. Abbreviations: EF, executive functioning;
PS, processing speed; VM, verbal memory; WM, working memory; IP, information processing; AT, attention.
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This report, as well as our previous report on this LGG patient
cohort,7 demonstrates that cognitive deficits are present in LGG
patients in a period of stable disease and that their performance
on cognitive tests is statistically significantly worse than that of
healthy controls. However, the deficits found are, on a group
level, relatively mild. In fact, the z scores on all domains tested
did not exceed 1.5 SD below the mean of healthy controls (the
threshold often used in the patient context to define clinically sig-
nificant cognitive dysfunction). Memory deficits in particular
seemed less prominently present in our cohort than in other pub-
lications on glioma patients.29,30 One explanation for this partic-
ular difference could be the use of a different neuropsychological
test. We tested verbal memory using visually presented stimuli,
while other reports frequently used verbal auditory-presented
stimuli. While still measuring the same construct (ie, verbal mem-
ory), a bias in results based on this difference cannot be excluded.
In addition, the reduction found in mental health does not ex-
ceed a standard deviation below the mean and hence probably
reflects only subtle compromise. Nevertheless, while cognitive
deficits and compromise in HRQOL may be subtle in nature, the
present report demonstrates the highly correlated relationship
of cognitive functioning and both generic and disease-specific
HRQOL. With most correlations being of moderate strength, it
seems likely that LGG patients with stable disease, who resumed
their daily activities, may be more aware of subtle or more pro-
nounced negative changes in their cognitive abilities. We suspect
that the priorities of LGG patients may shift along with their view
of the immediate and more distant future. However, these hy-
potheses cannot be confirmed by the present study due to its
cross-sectional nature. Thus, additional longitudinal studies are
needed.
Alternatively, in part, the associations found may be explained
by the nature of the neuropsychological tests and the neurologi-
cal disabilities of the participants. Visual and motor deficits in
particular may contribute to poorer performance on certain cog-
nitive tasks that depend on these skills, such as tests assessing
attentional functioning. Indeed, poor performance on timed
tasks in these patients can be attributed, in large part, to visual
and motor deficits.31 Where possible, interventions to improve
functioning in these areas may potentially contribute to better
cognitive functioning as well as better HRQOL.
We only investigated the association between HRQOL and cog-
nitive functioning in this study; it is likely that this association was
Table 3. Associations between cognitive functioning and generic
health-related quality of life in low-grade glioma patients
Low-grade gliomas (n¼ 190)
Physical Health (PCS) Mental Health (MCS)
Executive functioning r¼ 0.427, P, .001* r¼ 0.270, P, .001*
Processing speed r¼ 0.455, P, .001* r¼ 0.318, P, .001*
Verbal memory r¼ 0.265, P, .001* r¼ 0.184, P¼ .012
Working memory r¼ 0.393, P, .001* r¼ 0.250, P¼ .001*
Information processing r¼ 0.436, P, .001* r¼ 0.267, P, .001*
Attention r¼ 0.336, P, .001* r¼ 0.157, P¼ .036
*P, .00833.
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confounded by other patient-related factors such as fatigue,
sleep quality, anxiety, depression, and instrumental activities of
daily living (IADL), which have been reported to affect the daily
lives of patients as well.8,32 – 34 Although it is not yet available
as a validated instrument, a brain tumor-specific measure of
IADL is currently being developed at our institution. Because
this test includes adapted items based on IADL assessment in pa-
tients with dementia and focuses on their everyday functional
impairment resulting from cognitive deficits, it could prove to be
a highly relevant tool in the future in both clinical practice and the
research setting.
In conclusion, our results indicate that when cognitive func-
tioning is worse, LGG patients who are in a stable phase of their
disease experience worse physical and mental HRQOL. Further-
more, LGG patients who experience more cognitive deficits also
report more issues with disease-specific HRQOL, which is most
pronounced in the scales of future uncertainty, motor dysfunc-
tion, visual disorders, and seizures. Future longitudinal studies
should include measures of anxiety and depression, fatigue,
IADL, demographic characteristics, and clinical variables in
order to assess which other factors have an effect on these asso-
ciations. While beyond the scope of the present study, examining
associations between cognitive functioning and subscales, rather
than summary scales of generic HRQOL, could provide additional
information in future studies. Maintaining or even improving
HRQOL by preventing long-term cognitive sequelae, or rehabilita-
tion of cognitive deficits if prevention is not feasible, is an impor-
tant goal in the treatment of glioma patients. It is important to
understand the functional significance of cognitive impairments
in the everyday lives of LGG patients. Cognitive assessment of pa-
tients with gliomas cannot—or rather, should not—be performed
in isolation from assessment of its impact on psychosocial func-
tioning and HRQOL.
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